Ann Maddox, NP
Adult Health · Atlanta, GANPI 1689017832
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,498 of the $6,535 with a category attached, or 84.1%. It is spread thinly across 29 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,764 and has fallen 91.2% since, to $243 in 2025. Among adult health clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $27.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Actelion Pharmaceuticals US, Inc.$769
- AstraZeneca$666
- GSK$626
- Bayer$604
- Electromed, Inc.$570
- plus $2K from 23 others
What the payments were for
- Consulting fees$4006%
- Travel & lodging$5118%
- Food & beverage$5,49884%
- Education$1112%
- Gifts$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $1,346 |
| Actelion Pharmaceuticals US, Inc. | 24 | $769 |
| AstraZeneca(2 entities) | 21 | $666 |
| GSK | 46 | $626 |
| Bayer | 11 | $604 |
| Electromed, Inc. | 41 | $570 |
| Grifols USA, LLC | 10 | $238 |
| Amgen | 10 | $229 |
| Mylan Specialty L.p. | 10 | $198 |
| United Therapeutics Corporation | 10 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $157 |
| Boehringer Ingelheim | 8 | $149 |
| Merck | 5 | $131 |
| Regeneron Healthcare Solutions, Inc. | 5 | $118 |
| Sanofi | 4 | $106 |
| ANI Pharmaceuticals, Inc. | 4 | $88 |
| Baxter Healthcare | 2 | $57 |
| Johnson & Johnson(2 entities) | 2 | $53 |
| Chiesi USA, Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Insmed, Inc. | 1 | $28 |
| Inogen, Inc. | 2 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Novartis | 1 | $14 |
| Philips North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,269
- Adempas$400
- FASENRA$248
- UPTRAVI$131
- OPSUMIT$131
How this compares
$6,535 in reported general payments places this provider in the 90th percentile of 577 adult health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 60 | $1,355,807 |
| OpsumitMacitentan | 66 | $872,509 |
| AdempasRiociguat | 25 | $344,660 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 240 | $202,910 |
| OfevNintedanib Esylate | 15 | $188,680 |
| Ambrisentan | 84 | $163,435 |
| LetairisAmbrisentan | 11 | $140,422 |
| Tadalafil | 112 | $94,502 |
| NucalaMepolizumab | 24 | $85,995 |
| EliquisApixaban | 101 | $68,419 |
| Spiriva RespimatTiotropium Bromide | 67 | $46,323 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $31,758 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $21,547 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $21,447 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $19,912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $769 | $2,228,316126 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $626 | $350,167394 claims |
| BayerAdempas | $604 | $344,66025 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $149 | $254,915118 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $666 | $42,99490 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 577 adult health providers in Georgia.
Other adult health in Atlanta
- Patricia KeeganAtlanta$224K
- Diane WirthAtlanta$132K
- Barbara WeberAtlanta$74K
- Terry HackworthAtlanta$49K
- Jenina LagascaAtlanta$17K
- Caleb MagistroAtlanta$17K
- Charise GleasonAtlanta$14K
- Colleen LewisAtlanta$11K
- Dawnelle StedingAtlanta$9K
- Julie WebsterAtlanta$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.